9999999997-12-012971.txt : 20120828
9999999997-12-012971.hdr.sgml : 20120828
20120828091837
ACCESSION NUMBER: 9999999997-12-012971
CONFORMED SUBMISSION TYPE: CT ORDER
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20120828
DATE AS OF CHANGE: 20120828
20120828
20120828
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: IDENIX PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001093649
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 450478605
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: CT ORDER
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-49839
FILM NUMBER: 121058465
BUSINESS ADDRESS:
STREET 1: 60 HAMPSHIRE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-995-9800
MAIL ADDRESS:
STREET 1: 60 HAMPSHIRE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: NOVIRIO PHARMACEUTICALS LTD
DATE OF NAME CHANGE: 19990820
CT ORDER
1
filename1.pdf
begin 644 filename1.pdf
M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T%LP(#`@-C$R(#O$@1$B0A
MK50HRJZ:2H@+%UQ8:0]HUU')VW?&7LA"FU9-9!G;,[_M?_"W(@8.0H$:@DA`
M!#@,(5`2)`>5)"`%""XBN+IBMP=[EUIM#<[O4D&[.-R/1FQ:5Q9C629I,\9P
M&M).GUXT]3HU=LD6-U.6F8-=C48H_[*`'[IH#4YF(%@Z[I;I#/@'+EGVM#?/
M=[)Z[_-N[[A=F\I",A3L6N\_FGR[L^B3;%T[LL+TT+<_,3[NM25^]=;JY+PUP&$RZ^2`>3
MNMC,,I=/;6/L>L?F=5/JPH4>O"6%CCY97>3K<;4M#'"66E-^Q?\Y]O61EBPW
M^=[6#?O6*\45.M&M(M/9ZIQL(Y,4M]-#T
M2)]UIQ`2?3U^MV0H:QZ-`TI+OME_+PI
M*;M?ZG&L(!8"E$I<#Y*A4U%\&(9>AW'2^%U1%+NL/X>?QG[SMX:XG]0T=FYP
M)57BZ\`QP3HH=G1)2G(0=/'NK-5;08S/0>3J=2#^D\'P!083^38$7TN?Y)?T
MB?^@[[G1>U#_.W^_$\A/K]VGSS'7$41<'5_Z>,.)(HP?]5[S)];.:./GH^.H
M\]3GCHB^_&I[.4<[_S(X"\!!@"5+8?##0IE;F1S=')E86T-96YD;V)J
M#3$T(#`@;V)J#3P\+T9I;'1E`N&GR)(@8N1/N!R\#!
M/[PP/Z1X"9R0AAY$KP,'#@.;.HX[@2@9F,7;X)D\K5?1PK(].B%SV%JV3P,2
M6=0ETTC?79B;8/T5_3:PQS0(?+!=ZOH0S16F,S:8*%R)X'K:VC68FVFC5?8,3T.T2;Q31ZP"^F71@X]GO<3+#NO,P8
M?5M`VR_LU,+T!Z:S"!Z7X$Y&LOV,>-`28?[/:AU3U[W*Y\EW;+-2;%.>BW?X
M_1B7KW'"FUHD<599'DYD"*L\H3K7%=2-5/VNDJ7(.*P+"H[M3<+1!&R8+7]A
M8<#TE%"GGM8I]76J6SJFH1ZM!!NUL.Y(E2KJFJ<0YQ"?3AF"U*+(HU2(_0%+D>X%4:Q%G4)<\KB7;$>&6C6[+:]@7
M)8@<_^O[F%G3#>D8X3K"89O#R`KIB1KX>Y(U*3+?EX6,QZKK(X?%^U'L1%U!
M74`,2RL@A45#4II7C&9UAHM*W*X2;4/7L?^`/4X\!4QH3&D\2=LQ72O&3.ZJ
MQ>WD7'(75QJOY*>25]@;U6XLK+Q.YQ/'MA2P;
M=>&-_=[N86R8Q[EZ47&0>^68R#DPTA>9G-JRY#PM]#,H]BU1#=L115^W:G$-
MQ#2IA^##$]W2&07?9R]D]V*]$._%&BKDN?BW4Q4S%,]3>R:51,&,LZ(\%:4&
M70I)G,,1:T]YS3%C@!H2.5[)[)-$F*,D7_9!_#L\B-30(\KN)VF_3=6R:1*XFC*KGTQK[(
MLN)-6I-KEYAJV(B.KH\\UYCM3609R*IV**U0>=#I?9#;"D>
M'N[$\V6=9=$6K=]ND&.N\-&0ZQJV75Q+E2EMZ'%U,>B%/7'5Q7LZ(/IYH'GW#B)ND7;H6?='?PI);G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS
M.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835`@0V]R92`U
M+C(M8S`P,2`V,RXQ,SDT,SDL(#(P,3`O,#DO,C&%P+S$N,"\B/@H@("`@("`@
M("`\>&UP.D-R96%T941A=&4^,C`Q,BTP."TR-U0Q,3HT.#HU-BTP-#HP,#PO
M>&UP.D-R96%T941A=&4^"B`@("`@("`@(#QX;7`Z0W)E871O&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*
M("`@("`@("`@/'!D9CI0&UP34TZ26YS=&%N8V5)1#YU=6ED.C&UP34TZ26YS
M=&%N8V5)1#X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@(#POJ'
M5!:DZ@?,RQ"H,P%$#17WF;R6!,@E9;1)`Z
M=!$$2UVZV"2E@6#*\TE_OPZ=N]]SCR"AKK-VHU=$=MD6K_%),$6TD((A795:
M\Z;Y"C``=KH^<0T*96YD7!E+UA2968O5ULQ
M(#(@,5T^/G-T